All In MedTech

Device Trial Radar · NCT04280029

SELUTION SLR™ 014 In-stent Restenosis

SELUTION SLR™ 014 ISR: A Prospective Randomized Single Blind Multicenter Study to Assess the Safety and Effectiveness of the SELUTION SLR™ 014 Drug Eluting Balloon in the Treatment of Subjects With In-stent Restenosis

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 418 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

418

Actual

Start

Jul 6, 2020

Primary completion

Aug 15, 2025

Study completion Aug 2029

Sponsor

Lead sponsor
M.A. Med Alliance S.A.Not on our public-company list
Sponsor type
Industry
Collaborators
IQVIA Pty Ltd; Cordis US Corp.
First posted
Feb 21, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective, multi-center, randomized, single blind, controlled, noninferiority clinical trial. Subjects with previous bare-metal stent (BMS) or Drug-Eluting Stent (DES) and qualifying evidence for In-stent Restenosis (ISR) will be screened per the protocol inclusion and exclusion criteria. Eligible subjects will be randomized 1:1 to treatment with either the SELUTION SLR 014 DEB or Standard of Care (SOC) to include contemporary DES (zotarolimus-eluting stents \[ZES\] and everolimus-eluting stents \[EES\] only) or Balloon Angioplasty (BA). A maximum of 20% of patients randomized to SOC will be treated with BA. The primary endpoint will be Target Lesion Failure (TLF) at 12-months in the SOC group vs. the SELUTION SLR 014 DEB in all patients.

Conditions

  • Coronary Restenosis

Interventions

  • SELUTION SLR 014 DEBDevice

    The SELUTION Sustained Limus Release (SLR)™ 014 drug-eluting balloon (DEB) catheter is a combination product consisting of a standard percutaneous transluminal angioplasty (PTA) balloon catheter coated with a drug (Sirolimus).

  • Standard of CareDevice

    POBA or FDA-approved commercially available -limus eluting DES

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Target Lesion Failure (TLF)Time frame: 12 months post-index procedure

Locations

48 sites in 7 countries. Site status is shown where the registry gives one.

  • Loma Linda University

    Loma Linda, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Harbor-UCLA Medical Center

    Torrance, California

45 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.